Endoscopic Sleeve Gastroplasty - A New Tool to Manage Obesity.
- Author:
Deepanshu JAIN
1
;
Bharat Singh BHANDARI
;
Ankit ARORA
;
Shashideep SINGHAL
Author Information
- Publication Type:Review
- Keywords: Endoscopic sleeve gastroplasty; Obesity; Endoscopic bariatric therapy; Body mass index; Extra weight loss
- MeSH: Bariatric Surgery; Behavior Therapy; Body Mass Index; Endoscopy, Digestive System; Follow-Up Studies; Gastroplasty*; Humans; Incidence; Mortality; Obesity*; Pandemics; Treatment Outcome; Weight Loss
- From:Clinical Endoscopy 2017;50(6):552-561
- CountryRepublic of Korea
- Language:English
- Abstract: Obesity is a growing pandemic across the world. Dietary restrictions and behavior modifications alone have a limited benefit. Bariatric surgery, despite being the current gold standard, has limited acceptance by patients due to cost and associated morbidity. In our review, we have discussed nine original studies describing endoscopic sleeve gastroplasty (ESG). A total of 172 subjects successfully underwent ESG. Of 65 subjects with follow up data, 95.4% (62/65) had intact gastric sleeve confirmed via esophagogastroduodenoscopy or oral contrast study at the end of study specific follow up interval (the longest being 6 months). Individual studies reported a technical success rate for intact gastric sleeve from as low as 50% to as high as 100%. A statistically significant p < 0.05) weight loss was reported in seven of the eight studies with available data. None of the patients experienced any intra-procedure complications, and approximately 2.3% (4/172) of patients experienced major post-procedure complications; however, no mortality was reported. Majority of the studies reported relatively high incidence of minor post-procedure complications, which improved with symptomatic treatment alone. Good patient tolerance with comparable clinical efficacy in achieving and sustaining desired weight loss makes ESG an attractive option to consider among other bariatric therapies.
